Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-10-23-Speech-3-096"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20021023.2.3-096"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
".
The definition of an internal market for medicinal products must not only achieve better standards of health in the European Union but must also stimulate scientific and technological innovation with a view to the development of new medicines and to speeding up the manufacture and commercialisation of generic products. On the main issues being debated at this first reading I feel that: 1- without this meaning the total elimination of the decentralised procedure (national with mutual recognition), I believe it is crucial, where the marketing authorisation is concerned, to demonstrate increasing commitment to the centralised procedure (via the European Agency for the Evaluation of Medicinal Products), in particular when it comes to new active substances, in the aim of achieving more rapid access for sufferers to new medicines and in the aim of ensuring that small and medium-sized enterprises are not penalised; 2- authorisation must be granted for the marketing of generic products whose reference medicine has been authorised for more than eight years in a Member State or in the Community (and not ten years, as the Commission proposes); 3- with regard to information, the Commission proposal is ambiguous, whereas it is crucial to ensure the ban on direct advertising."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples